Should Patients With Non-Muscle-Invasive Bladder Cancer Discontinue Fibrin Clot Inhibitors During BCG?
Niyati LoboPatrick J HensleyKelly K BreeGraciela M Nogueras-GonzalezNeema NavaiColin P DinneyAshish M KamatPublished in: BJU international (2021)
The use of fibrin clot inhibitors was not associated with adverse oncological outcomes in a large contemporary cohort of patients receiving adequate intravesical BCG for non-muscle invasive bladder cancer. Based on these results, fibrin clot inhibitors may be safely continued during BCG immunotherapy.